Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: An updated meta-analysis

European Journal of Clinical Pharmacology

Volumn 66, Issue 8, 2010, Pages 813-821

  An, Mao Mao ^a   Zou, Zui ^b   Shen, Hui ^c   Liu, Ping ^d   Chen, Meng Li ^d   Cao, Yong Bing ^a   Jiang, Yuan Ying ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUWAI HOSPITAL   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Bevacizumab; Chemotherapy; Meta analysis; Raised blood pressure

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PEMETREXED;

ARTICLE; BLOOD PRESSURE; BREAST METASTASIS; CANCER PATIENT; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; HUMAN; INCIDENCE; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MALIGNANT MESOTHELIOMA; META ANALYSIS; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SOLID TUMOR; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; AUTONOMIC NERVOUS SYSTEM DISEASES; BREAST NEOPLASMS; CARCINOMA, RENAL CELL; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; META-ANALYSIS AS TOPIC; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77955523015     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0815-4     Document Type: Article

References (34)

1. J Folkman 1971 Tumor angiogenesis: therapeutic implications N Engl J Med 285 1182 1186 1:STN:280:DyaE38%2FgvVCqsQ%3D%3D 4938153
2. J Folkman 2002 Role of angiogenesis in tumor growth and metastasis Semin Oncol 29 6 suppl 16 15 18 1:CAS:528:DC%2BD3sXlvFSqtg%3D%3D 12516034
3. HP Gerber N Ferrara 2005 Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 671 680 1:CAS:528:DC%2BD2MXhtVWnsb0%3D 15705858
4. BJ Giantonio PJ Catalano NJ Meropol PJ O'Dwyer EP Mitchell SR Alberts MA Schwartz AB Benson 3rd 2007 Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 1539 1544 10.1200/JCO.2006.09.6305 1:CAS:528: DC%2BD2sXlsVyntbc%3D 17442997 (Pubitemid 46733080)
5. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim J Berlin A Baron S Griffing E Holmgren N Ferrara G Fyfe B Rogers R Ross F Kabbinavar 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2335 2342 10.1056/NEJMoa032691 1:CAS:528:DC%2BD2cXks1Gjt74%3D 15175435 (Pubitemid 38702844)
6. HI Hurwitz L Fehrenbacher JD Hainsworth W Heim J Berlin E Holmgren J Hambleton WF Novotny F Kabbinavar 2005 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer J Clin Oncol 23 3502 3508 10.1200/JCO.2005.10.017 1:CAS:528:DC%2BD2MXlsVyhsrs%3D 15908660
7. F Kabbinavar HI Hurwitz L Fehrenbacher NJ Meropol WF Novotny G Lieberman S Griffing E Bergsland 2003 Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer J Clin Oncol 21 60 65 10.1200/JCO.2003.10.066 1:CAS:528:DC%2BD2cXpsVWru7Y%3D 12506171
8. LB Saltz S Clarke E Díaz-Rubio W Scheithauer A Figer R Wong S Koski M Lichinitser TS Yang F Rivera F Couture F Sirzén J Cassidy 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2013 2019 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D 18421054
9. FF Kabbinavar J Schulz M McCleod T Patel JT Hamm JR Hecht R Mass B Perrou B Nelson WF Novotny 2005 Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 3697 3705 10.1200/JCO.2005.05.112 1:CAS:528:DC%2BD2MXlslWntr0%3D 15738537
10. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati R Lilenbaum DH Johnson 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2542 2550 10.1056/NEJMoa061884 1:CAS:528:DC%2BD28XhtlWqsbzI 17167137 (Pubitemid 44917502)
11. K Miller M Wang J Gralow M Dickler M Cobleigh EA Perez T Shenkier D Cella NE Davidson 2007 Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2666 2676 10.1056/NEJMoa072113 1:CAS:528:DC%2BD1cXisVOnsg%3D%3D 18160686
12. D Miles A Chan G Romieu LY Dirix J Cortes X Pivot P Tomczak T Taran N Harbeck GG Steger 2008 Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC):AVADO Proc Am Soc Clin Oncol 26 15 Suppl LBA1011
13. KD Miller LI Chap FA Holmes MA Cobleigh PK Marcom L Fehrenbacher M Dickler BA Overmoyer JD Reimann AP Sing V Langmuir HS Rugo 2005 Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer J Clin Oncol 23 792 799 10.1200/JCO.2005.05.098 1:CAS:528:DC%2BD2MXitVKitrk%3D 15681523 (Pubitemid 46224178)
14. BI Rini S Halabi JE Rosenberg WM Stadler DA Vaena SS Ou L Archer JN Atkins J Picus P Czaykowski J Dutcher EJ Small 2008 Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 5422 5428 10.1200/JCO.2008.16.9847 1:CAS:528:DC%2BD1MXhslClsA%3D%3D 18936475
15. B Escudier A Pluzanska P Koralewski A Ravaud S Bracarda C Szczylik C Chevreau M Filipek B Melichar E Bajetta V Gorbunova JO Bay I Bodrogi A Jagiello-Gruszfeld N Moore 2007 Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a odifyzed, double-blind phase III trial Lancet 370 2103 2111 10.1016/S0140-6736(07)61904-7 18156031 (Pubitemid 350296300)
16. Genentech. Bevacizumab prescribing information. Available at: http://www.Gene.com/gene/products/information/oncology/avastin/. Accessed 27 Oct 2008
17. M Reck J von Pawel P Zatloukal R Ramlau V Gorbounova V Hirsh N Leighl J Mezger V Archer N Moore C Manegold 2009 Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 1227 1234 10.1200/JCO.2007.14.5466 1:CAS:528:DC%2BD1MXktFKhsL0%3D 19188680
18. DH Johnson L Fehrenbacher WF Novotny RS Herbst JJ Nemunaitis DM Jablons CJ Langer RF DeVore 3rd J Gaudreault LA Damico E Holmgren F Kabbinavar 2004 Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer J Clin Oncol 22 2184 2191 10.1200/JCO.2004.11.022 1:CAS:528:DC%2BD2cXpsVWltrg%3D 15169807 (Pubitemid 41095154)
19. RS Herbst VJ O'Neill L Fehrenbacher CP Belani PD Bonomi L Hart O Melnyk D Ramies M Lin A Sandler 2007 Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer J Clin Oncol 25 4743 4750 10.1200/JCO.2007.12.3026 1:CAS:528: DC%2BD2sXhtlCgsLnP 17909199 (Pubitemid 350086476)
20. CJ Allegra G Yothers MJ O'Connell S Sharif N Wolmark 2008 Initial safety report of NSABP C-08, a randomized phase III study of odify ed 5-fluorouracil (5-FU)/leucovorin (LCV) and oxaliplatin (OX) (mFOLFOX6) with or without bevacizumab (bev) in the adjuvant treatment of patients with stage II/III colon cancer Proc Am Soc Clin Oncol 26 15 Suppl 4006
21. E Van Cutsem WL Vervenne J Bennouna Y Humblet S Gill JL Van Laethem C Verslype W Scheithauer A Shang J Cosaert MJ Moore 2009 Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer J Clin Oncol 27 2231 2237 10.1200/JCO.2008.20.0238 19307500
22. HL Kindler D Niedzwiecki D Hollis E Oraefo D Schrag H Hurwitz HL McLeod MF Mulcahy RL Schilsky RM Goldberg 2007 A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) Proc Am Soc Clin Oncol 25 18 Suppl 4508
23. T Karrison HL Kindler DR Gandara C Lu TL Guterz K Nichols H Chen WM Stadler E Vokes 2007 Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM) J Clin Oncol (Meeting Abstracts) 25 7526
24. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434
25. X Zhu S Wu WL Dahut CR Parikh 2007 Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis Am J Kidney Dis 49 186 193 10.1053/j.ajkd.2006.11.039 1:CAS:528:DC%2BD2sXis1Kgu78%3D 17261421 (Pubitemid 46178407)
26. AR Jadad RA Moore D Carroll C Jenkinson DJ Reynolds DJ Gavaghan HJ McQuay 1996 Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17 1 12 10.1016/0197-2456(95)00134-4 1:STN:280:DyaK28zgvVCmug%3D%3D 8721797 (Pubitemid 26120810)
27. KS Khan S Daya A Jadad 1996 The importance of quality of primary studies in producing unbiased systematic reviews Arch Intern Med 156 661 666 10.1001/archinte.156.6.661 1:STN:280:DyaK283gsF2qsA%3D%3D 8629879 (Pubitemid 26095017)
28. D Moher AR Jadad P Tugwell 1996 Assessing the quality of randomized controlled trials. Current issues and future directions Int J Technol Assess Health Care 12 195 208 10.1017/S0266462300009570 1:STN:280:DyaK283pt12quw%3D%3D 8707495
29. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 177 188 10.1016/0197-2456(86)90046-2 1:STN:280:DyaL2s7gsVamtA%3D%3D 3802833 (Pubitemid 17189972)
30. S Wu JJ Chen A Kudelka J Lu X Zhu 2008 Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis Lancet Oncol 9 117 123 10.1016/S1470-2045(08)70003-2 1:CAS:528: DC%2BD1cXhsVOnu7k%3D 18221915
31. X Zhu K Stergiopoulos S Wu 2009 Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis Acta Oncol 48 9 17 10.1080/02841860802314720 1:CAS:528: DC%2BD1cXhsFagtbjI 18752081
32. TK Choueiri SA Vaziri E Jaeger P Elson L Wood IP Bhalla EJ Small V Weinberg N Sein J Simko AR Golshayan L Sercia M Zhou FM Waldman BI Rini RM Bukowski R Ganapathi 2008 von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma J Urol 180 860 866 10.1016/j.juro.2008.05.015 1:CAS:528: DC%2BD1cXhtVKmsbvE 18635227
33. J Lau JPA Ioannidis CH Schmid 1997 summing up the evidence: one answer is not always enough Lancet 351 123 127 10.1016/S0140-6736(97)08468-7
34. SG Thompson 1994 Why sources of heterogeneity in meta-analysis should be investigated Br Med J 309 1351 1355 1:STN:280:DyaK2M7ntVelsQ%3D%3D